| Phase 01 trial |
|
Phase 0
|
NCT06629428 |
Nov 2025 → Jun 2026 overdue |
relapsing-remitting multiple sclerosis |
Georgia State University |
Recruiting
|
No outcome recorded
|
| Phase 110 trials |
|
Phase 1
|
NCT04635683 |
Sep 2022 → Dec 2023 |
MALT lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, mantle cell lymphoma +2 |
Yazeed Sawalha |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT04806035 |
Apr 2021 → Jun 2024 |
Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma +1 |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03778073 |
Apr 2019 → May 2022 |
B-cell non-Hodgkin lymphoma, Richter transformation |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03804996 |
Mar 2019 → Feb 2024 |
lymphoma |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03671590 |
Sep 2018 → May 2024 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT02276963 |
Jan 2016 → Jul 2017 |
neuromyelitis optica |
Johns Hopkins University |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02535286 |
Sep 2015 → Nov 2021 |
Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02006485 |
Dec 2013 → Oct 2019 |
B-cell chronic lymphocytic leukemia |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01744912 |
Nov 2012 → Feb 2014 |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT01098188 |
Nov 2008 → Aug 2011 |
B-cell chronic lymphocytic leukemia |
LFB |
Completed
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT05152459 |
May 2023 → Dec 2024 |
follicular lymphoma |
City of Hope Medical Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT04692155 |
Aug 2021 → Jun 2022 |
mantle cell lymphoma |
University of Alabama at Birmingham |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT02013128 |
Jan 2014 → Dec 2015 |
B-cell chronic lymphocytic leukemia, mantle cell lymphoma |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01647971 |
Jul 2012 → May 2015 |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, primary central nervous system lymphoma |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
| Phase 214 trials |
|
Phase 2
|
NCT07673744 |
Jul 2026 → Jul 2028 expected |
myasthenia gravis |
TG Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07680946 |
Jul 2026 → Dec 2028 expected |
schizophrenia |
TG Therapeutics, Inc. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07503873 |
Apr 2026 → May 2027 expected |
multiple sclerosis |
TG Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07103746 |
Feb 2026 → Aug 2028 expected |
autoimmune disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04783415 |
Mar 2021 → Jul 2022 overdue |
mantle cell lymphoma |
City of Hope Medical Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04149821 |
Feb 2021 → Jan 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Weill Medical College of Cornell University |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04624633 |
Dec 2020 → Dec 2023 overdue |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Jennifer R. Brown, MD, PhD |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04508647 |
Nov 2020 → Jul 2022 |
follicular lymphoma, marginal zone lymphoma |
University of Colorado, Denver |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04016805 |
Aug 2019 → May 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03828448 |
Jul 2019 → May 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03207256 |
Aug 2017 → May 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03381170 |
Jun 2017 → Nov 2022 |
relapsing-remitting multiple sclerosis |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02738775 |
May 2016 → Sep 2017 |
multiple sclerosis |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02656303 |
Jan 2016 → May 2022 |
B-cell chronic lymphocytic leukemia |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
| Phase 2/33 trials |
|
Phase 2/3
|
NCT07220252 |
Jul 2026 → Jan 2030 expected |
multiple sclerosis |
TG Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT03801525 |
May 2019 → Dec 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2/3
|
NCT02793583 |
May 2016 → May 2022 |
chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
| Phase 37 trials |
|
Phase 3
|
NCT07211633 |
Jul 2025 → Oct 2026 expected |
multiple sclerosis |
TG Therapeutics, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05877963 |
Jun 2023 → Dec 2027 expected |
multiple sclerosis |
TG Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04130997 |
Nov 2019 → May 2032 expected |
multiple sclerosis |
TG Therapeutics, Inc. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT03277261 |
Sep 2017 → Jul 2020 |
relapsing-remitting multiple sclerosis |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT03277248 |
Aug 2017 → Aug 2020 |
relapsing-remitting multiple sclerosis |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02612311 |
Nov 2015 → Feb 2023 |
B-cell chronic lymphocytic leukemia |
TG Therapeutics, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT02301156 |
Jan 2015 → Apr 2020 |
B-cell chronic lymphocytic leukemia |
TG Therapeutics, Inc. |
Completed
|
No outcome recorded
|
| Phase 43 trials |
|
Phase 4
|
NCT07389590 |
Feb 2026 → Oct 2028 expected |
multiple sclerosis |
Johns Hopkins University |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT07225361 |
Nov 2025 → Mar 2029 expected |
relapsing-remitting multiple sclerosis |
Northwestern University |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT03535298 |
Jan 2019 → Jul 2027 expected |
relapsing-remitting multiple sclerosis |
The Cleveland Clinic |
Active not recruiting
|
No outcome recorded
|